BRIEF-Nurix Licenses A Drug Discovery Program To Sanofi Targeting A Novel Transcription Factor For Autoimmune Diseases

Reuters

04-02

BRIEF-Nurix Licenses A Drug Discovery Program To <a href="https://laohu8.com/S/GCVRZ">Sanofi</a> Targeting A Novel Transcription Factor For Autoimmune Diseases

April 2 (Reuters) - Nurix Therapeutics Inc NRIX.O:

NURIX LICENSES A DRUG DISCOVERY PROGRAM TO SANOFI TARGETING A NOVEL TRANSCRIPTION FACTOR FOR AUTOIMMUNE DISEASES
NURIX THERAPEUTICS- RECEIVES $15 MILLION LICENSE EXTENSION FEE FROM SANOFI
NURIX THERAPEUTICS- ELIGIBLE FOR ADDITIONAL $465 MILLION IN MILESTONES AND ROYALTIES

Source text: ID:nGNXp0z2

Further company coverage: NRIX.O

((Reuters.Briefs@thomsonreuters.com;))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2524467402"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2524467402\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2524467402?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-02 20:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524467402","market":"us","top_or_hot":-1,"title":"BRIEF-Nurix Licenses A Drug Discovery Program To Sanofi Targeting A Novel Transcription Factor For Autoimmune Diseases","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Nurix Licenses A Drug Discovery Program To <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> Targeting A Novel Transcription Factor For Autoimmune Diseases</title></head><body><p><span>April 2 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/NRIX\">Nurix Therapeutics</a> Inc <span>NRIX.O</span>:</p><ul><li><p>NURIX LICENSES A DRUG DISCOVERY PROGRAM TO SANOFI TARGETING A NOVEL TRANSCRIPTION FACTOR FOR AUTOIMMUNE DISEASES</p></li><li><p>NURIX THERAPEUTICS- RECEIVES $15 MILLION LICENSE EXTENSION FEE FROM SANOFI</p></li><li><p>NURIX THERAPEUTICS- ELIGIBLE FOR ADDITIONAL $465 MILLION IN MILESTONES AND ROYALTIES</p></li></ul><p>Source text: <span>ID:nGNXp0z2</span></p><p>Further company coverage: <span>NRIX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Nurix Licenses A Drug Discovery Program To Sanofi Targeting A Novel Transcription Factor For Autoimmune Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Nurix Licenses A Drug Discovery Program To Sanofi Targeting A Novel Transcription Factor For Autoimmune Diseases\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-04-02 20:10</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Nurix Licenses A Drug Discovery Program To <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> Targeting A Novel Transcription Factor For Autoimmune Diseases</title></head><body><p><span>April 2 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/NRIX\">Nurix Therapeutics</a> Inc <span>NRIX.O</span>:</p><ul><li><p>NURIX LICENSES A DRUG DISCOVERY PROGRAM TO SANOFI TARGETING A NOVEL TRANSCRIPTION FACTOR FOR AUTOIMMUNE DISEASES</p></li><li><p>NURIX THERAPEUTICS- RECEIVES $15 MILLION LICENSE EXTENSION FEE FROM SANOFI</p></li><li><p>NURIX THERAPEUTICS- ELIGIBLE FOR ADDITIONAL $465 MILLION IN MILESTONES AND ROYALTIES</p></li></ul><p>Source text: <span>ID:nGNXp0z2</span></p><p>Further company coverage: <span>NRIX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NRIX","symbol_name":"Nurix Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QF1D2:1","article_id":"2524467402","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524467402","pubTimestamp":1743595844,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Nurix Licenses A Drug Discovery Program To Sanofi Targeting A Novel Transcription Factor For Autoimmune DiseasesApril 2  - Nurix Therapeutics Inc NRIX.O:NURIX LICENSES A DRUG DISCOVERY PROGRAM TO SANOFI TARGETING A NOVEL TRANSCRIPTION FACTOR FOR AUTOIMMUNE DISEASESNURIX THERAPEUTICS- RECEIVES $15 MILLION LICENSE EXTENSION FEE FROM SANOFINURIX THERAPEUTICS- ELIGIBLE FOR ADDITIONAL $465 MILLION IN MILESTONES AND ROYALTIESSource text: ID:nGNXp0z2Further company coverage: NRIX.O ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NRIX":"Nurix Therapeutics","BK4139":"生物科技"},"translate_title":"简介-Nurix向赛诺菲授权一项针对自身免疫性疾病的新型转录因子的药物发现计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRIX":0.9},"content_text":"BRIEF-Nurix Licenses A Drug Discovery Program To Sanofi Targeting A Novel Transcription Factor For Autoimmune DiseasesApril 2 (Reuters) - Nurix Therapeutics Inc NRIX.O:NURIX LICENSES A DRUG DISCOVERY PROGRAM TO SANOFI TARGETING A NOVEL TRANSCRIPTION FACTOR FOR AUTOIMMUNE DISEASESNURIX THERAPEUTICS- RECEIVES $15 MILLION LICENSE EXTENSION FEE FROM SANOFINURIX THERAPEUTICS- ELIGIBLE FOR ADDITIONAL $465 MILLION IN MILESTONES AND ROYALTIESSource text: ID:nGNXp0z2Further company coverage: NRIX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}